Dena C Howerton, CNM | |
201 Walls Dr Ste 503, Cleburne, TX 76033-4006 | |
(817) 984-9057 | |
Not Available |
Full Name | Dena C Howerton |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 201 Walls Dr Ste 503, Cleburne, Texas |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1134285562 | NPI | - | NPPES |
8Y8491 | Other | TX | BLUE CROSS BLUE SHIELD |
199448502 | Medicaid | TX | |
199448501 | Medicaid | TX |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367A00000X | Advanced Practice Midwife | AP110663 (Texas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dena C Howerton, CNM 201 Walls Dr Ste 503, Cleburne, TX 76033-4006 Ph: (817) 984-9057 | Dena C Howerton, CNM 201 Walls Dr Ste 503, Cleburne, TX 76033-4006 Ph: (817) 984-9057 |
News Archive
The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood.
LensAR, Inc., the leading developer of next generation laser technology for cataract surgery and presbyopia, today announced that the company has received 510(k) clearance from the FDA for use of the LensAR Laser System for anterior capsulotomy during cataract surgery.
Diabetics can face a five times increase in the risk of developing cardiovascular disease (CVD) than non-diabetics. This leads to a seven to ten year reduction in life expectancy and a higher probability of suffering a fatal heart attack. These sad statistics have prompted the European Society of Cardiology (ESC) to mark World Diabetes Day on 14 November 2010 by emphasising the simple measures that diabetes patients should adopt to slow-down the progression of CVD and greatly improve their quality of life.
"The potential for antiretroviral medicine to reduce transmission of HIV and tuberculosis has been demonstrated, but the challenges of using treatment to prevent infection will need to be tackled country by country, and with focus on people for whom it will have the biggest impact, the latest bulletin on HIV treatment from the World Health Organization says," the Center for Global Health Policy's "Science Speaks" blog reports.
› Verified 9 days ago